Dermatology Times Newsletter

To view this email as a web page, click here.

New drug application submitted for acne topical

Cassiopea SpA submitted a New Drug Application (NDA) to the U.S. Federal Drug Administration (FDA) for its novel acne treatment, clascoterone cream 1%, according to a company announcement released today.

FDA accepts new drug application for tazarotene lotion

The U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for Ortho Dermatologics’ novel tazarotene O.045% lotion (IDP-123) with a PDUFA action date of Dec. 22, 2019, according a recent announcement from the company.

How to keep patients on-track with rosacea regimens

Combination therapies for rosacea only work when patients continue their follow-up regimens. When do adherence issues most commonly pop up, and how do we address them when they do?

Find out in this Dermatology Times podcast.

From our Latest Issue

Building a body business

FDA clears non-contact laser energy device for abdominal fat reduction

Preserving medically-oriented dermatologists

Do you know an individual whose revolutionary ideas have refined the practice of dermatology?

Help us identify physicians and researchers in the field of dermatology whose dedication to the field has resulted in successful innovations and has inspired, informed, or improved the treatment of patients with skin disorders.

Nominate a leader today for the 2020 Giants of DermatologyTM recognition program.

JOB OPPORTUNITIES

CA - Integrated Dermatology

CO-Integrated Dermatology

CT - Integrated Dermatology

District of Columbia-Integrated Dermatology

MA - Integrated Dermatology

MD - Integrated Dermatology

MS - Integrated Dermatology

National - Integrated Dermatology

NJ - Integrated Dermatology

NJ - Practice for Sale

NV - Integrated Dermatology

VA - Integrated Dermatology

VT - Integrated Dermatology

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.